

RECEIVED
CENTRAL FAX CENTER

JUN 13 2005

AstraZeneca 

Facsimile

Date: June 13, 2005

Fax No.: 703-872-9306

To: USPTO

Art Unit: 1624

Appln. No.: 10/714,448

Filing Date: November 17, 2003

Docket No.: A2264-2P US

Title: Novel Compounds

From: Jianzhong Shen

Customer No.: 22466

No. of Pages: 8
(including this one)

If transmission is not complete or is illegible, please contact me at 302-885-0091.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that the following correspondence is being facsimile transmitted to the
United States Patent and Trademark office on: June 13, 2005Liz Ashton
Typed or Printed Name
SignatureAttachments

- 1) Revocation of POA with New POA and Change of Correspondence Address
- 2) Statement under 37 CFR 3.73(b)
- 3) Copy of Recorded Assignment

Information contained in this fax may be confidential and/or legally privileged. This fax is intended to be reviewed initially by only the individual or legal entity named above. If the reader of this transmittal page is not the intended recipient or a representative of the intended recipient, you are hereby notified that any reading, dissemination or copying of this fax or the information contained herein is prohibited. If you have received this fax in error please immediately notify the sender by telephone and return this fax to the sender at the address below. Thank you.

AstraZeneca
Global Intellectual Property
1800 Concord Pike
Wilmington DE-19850-5437Tel: +1 302 886 3000
Fax: +1 302 886 8221
www.astrazeneca-us.comAstraZeneca Pharmaceuticals LP
1800 Concord Pike
Wilmington, Delaware 19850-5438
USA

RECEIVED
CENTRAL FAX CENTER

JUN 13 2005

PTO/SFV02 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/714,448
	Filing Date	November 17, 2003
	First Named Inventor	Brown
	Art Unit	1624
	Examiner Name	Unknown
	Attorney Docket Number	A2264-2P US

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number:

22466

☒ Please change the correspondence address for the above-identified application to:☒ The address associated with
Customer Number:

22466


OR

<input type="checkbox"/> Firm or Individual Name				
Address				
City		State		Zip
Country				
Telephone			Email	

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			
Name	Paul Danerley		
Date	2 June 2005	Telephone	44 20 73045324

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

PTO/SU/SA (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Brown et al.Application No./Patent No.: 10/714,448Filed/Issue Date: November 17, 2003Entitled: Novel CompoundsAstraZeneca AB
(Name of Assignee)a corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ (the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 013626, Frame 0358, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Paul Denorlev
Signature2 June 2005
DatePaul Denorlev
Printed or Typed Name44 20 73045324
Telephone NumberDirector, IP Strategy
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES
PATENT AND
TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

JUN 13 2005

MAY 06, 2003

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

FITCH, KVEN, TABIN & FLANNERY
MICHAEL A. SANZO
1801 K STREET, N.W., SUITE 401L
WASHINGTON, D.C. 20006-1201



102329591A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 10/21/2002

REEL/FRAME: 013626/0358
NUMBER OF PAGES: 5

DRTEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
BROWN, WILLIAM

DOC DATE: 05/27/2002

ASSIGNOR:
WALPOLE, CHRISTOPHER

DOC DATE: 05/23/2002

ASSIGNOR:
FLOBECK, NIKLAS

DOC DATE: 06/13/2002

ASSIGNEE:
ASTRAZNECA AB
S-151 85 SODERTALJK, SWEDEN

SERIAL NUMBER: 10149981
PATENT NUMBER:

FILING DATE: 10/21/2002
ISSUE DATE:

RECEIVED

MAY - 9 2003

FETTER

013626/0358 PAGE 2

MARY BENTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

FORM 603 (Rev. 6-5)		U.S. DEPARTMENT OF COMMERCE	
DOMESTIC (201/201) (a-p. 4-10)		PATENT AND TRADEMARK OFFICE	
To the Honorable Com		102329591	
1. Name of conveying party(ies): William Brown, Christopher Walpole, Niklas Plobeck		2. Name and address of receiving party(ies): Name: <u>Astrazeneca AB</u> Internal Address: _____ Street Address: _____ City/State/ZIP: <u>S-151 85 Södertälje</u> <u>SWEDEN</u>	
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <u>10/21/02</u>		Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____		Execution Date: <u>May 27, 2002, May 23, 2002 and June 13, 2002</u>	
4. Application number(s) or parent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) <u>10/142,981</u> B. Patent No.(s) _____ Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Michael A. Sanzo</u> Internal Address: _____ Street Address: <u>Fitch, Even, Tabin & Flannery</u> <u>1801 K Street, N.W.</u> <u>Suite 4011</u> City/State/ZIP: <u>Washington, D.C. 20005-1201</u>		6. Total number of applications and patents involved: <u>1</u> 7. Total Fee (37 C.F.R. § 3.41) \$ <u>40.00</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: <u>06-1135 Under Order No. 7367/73249</u> <small>(A check payable to the U.S. Patent and Trademark Office must be deposited in the account.)</small>	
DO NOT USE THIS SPACE			
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Michael A. Sanzo <u>Michael A. Sanzo</u> <u>October 29, 2002</u> Name of Person Signing Signature Date Total number of pages including cover sheet, attachments, and document: <u>3</u>			

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

FORM 603.WP9

10/27/02 10:00PM 00600553 05/135 10/149581
07/18/02 09.00 PM


PATENT/Docket No.: A2264-1P USAssignment to AstraZeneca AB

Title: NOVEL COMPOUNDS
Inventors: BROWN, William; WAI, POLE, Christopher; PLOBECK, Niklas
PCT Appl. No: PCT/SE00/02562
Intn'l Filing Date: 15 December 2000
Execution Date of Application:
Country of PCT Receiving Office: Sweden

As a below-named inventor, I hereby declare that:

My post office address is as stated below under my signature and I am named as inventor of the inventions or discoveries (herein-INVENTIONS) as described in the patent application (herein APPLICATION) identified above. In view of valuable consideration, receipt thereof is hereby acknowledged, I do hereby assign and transfer unto AstraZeneca AB, a corporation of Sweden having a place of business at Södertälje, its successors and assigns, my entire interest in and the full and exclusive right to the INVENTIONS, the APPLICATION and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries, and any and all Letters Patent (and certificates of invention or similar certificates) (herein PATENTS) which may be granted based upon the INVENTIONS or the APPLICATION or related applications or counterparts in other countries; said transfer and assignment being applicable throughout the world. I hereby authorize and request officials of patent offices in any and all countries of the world to issue any and all of the PATENTS, when granted, to AstraZeneca AB, its successors and assigns, as the assignee of my entire right, title, and interest in and to the same. I agree that I will communicate to AstraZeneca AB, or its representatives, any facts known to me respecting the invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications; execute all necessary assignment papers to cause any and all of the PATENTS to be issued to AstraZeneca AB; make all rightful oaths; and generally do everything possible to aid AstraZeneca AB, its successors and assigns, to obtain and enforce proper protection for the INVENTION in any and all countries throughout the world.


FULL NAME OF FIRST/SOLE INVENTOR: BROWN, William

Signature of Inventor: 

Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9, Canada

Date: May 27 2002


FULL NAME OF SECOND/JOINT INVENTOR: WALPOLÉ, Christopher

Signature of Inventor: 

Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9, Canada

Date: May 23 2002

FULL NAME OF THIRD/JOINT INVENTOR: PLOBECK, Niklas

Signature of Inventor: 

Address: AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9, Canada

Date: June 13 2002